KAIROS PHARMA, LTD. Deferred Tax Assets, Operating Loss Carryforwards
KAIROS PHARMA, LTD. (KAPA) had Deferred Tax Assets, Operating Loss Carryforwards of $2.77 million as of 2025-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Notes › Income Taxes › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsOperatingLossCarryforwards · last filed 2026-03-31
- 2025-12-31: Deferred Tax Assets, Operating Loss Carryforwards $2.77M.
- 2024-12-31: Deferred Tax Assets, Operating Loss Carryforwards $1.20M.
- 2023-12-31: Deferred Tax Assets, Operating Loss Carryforwards $857.00K.
| Period end | Deferred Tax Assets, Operating Loss Carryforwards |
|---|---|
| 2025-12-31 | $2.77M 10-K · filed 2026-03-31 |
| 2024-12-31 | $1.20M 10-K · filed 2026-03-31 |
| 2023-12-31 | $857.00K 10-K · filed 2025-04-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |